GROWTH HORMONE AXIS / FAQ
Questions the Literature Answers
Plainly stated, citation-grounded responses to the questions readers most often bring to these three GHRH analogs.
What is CJC-1295?
CJC-1295 is a synthetic peptide built on the first 29 residues of human growth hormone-releasing hormone (GHRH), carrying four amino-acid substitutions that protect it from enzymatic breakdown and stabilize its receptor-binding shape [7]. In its DAC (Drug Affinity Complex) variant, an additional chemical linker allows it to bind covalently to serum albumin in the bloodstream, extending its half-life from the two-minute lifespan of natural GHRH to roughly five to eight days [4]. It is a research chemical with no approved human indication [1].
What does CJC-1295 do?
In human studies, CJC-1295 produced dose-dependent two- to ten-fold increases in mean plasma GH lasting six days or more, and 1.5- to three-fold increases in IGF-1 lasting nine to eleven days after a single subcutaneous dose [4]. Crucially, these elevations did not flatten the natural pulsatile rhythm of GH secretion — the frequency and magnitude of GH bursts were statistically unchanged [5]. In rats, it showed a four-fold increase in GH area-under-the-curve compared with unmodified GHRH and was detectable in plasma beyond 72 hours [7]. There are no approved clinical applications.
Is CJC-1295 safe?
The published human data are limited to pharmacokinetic studies in healthy adults, which were not designed as comprehensive safety assessments. Long-term safety in humans is unknown [1]. Known concerns from the literature include: theoretical cancer risk from sustained IGF-1 elevation, fluid retention and edema, and effects on insulin sensitivity [1][4]. The original DAC development program (ConjuChem) was discontinued; a patient death during that era is cited in connection with the halted Phase 2 trial, though a causal link to CJC-1295 was not established in the public record. CJC-1295 is not an approved drug, and no dose is listed here.
What is the difference between CJC-1295 DAC and CJC-1295 no-DAC?
This is perhaps the most important distinction on this desk for CJC-1295 specifically. CJC-1295 with DAC (the albumin-binding variant) has a measured plasma half-life of approximately 5.8–8.1 days, sustaining GH and IGF-1 elevation across a week from a single dose [4]. CJC-1295 without DAC — also called Modified GRF 1-29 or Mod GRF(1-29) — retains the four stabilizing substitutions but lacks the albumin-binding handle, making it a short-acting peptide with a half-life measured in minutes rather than days. They are pharmacokinetically entirely different compounds, despite sharing a similar name; conflating them is the single most common source of confusion in community protocols [7].
What is sermorelin?
Sermorelin is the first 29 amino acids of human growth hormone-releasing hormone — the minimum fragment that retains full activity at the GHRH receptor [10]. It was the active ingredient in an FDA-approved drug for pediatric GH deficiency, withdrawn from the US market in 2008 for commercial reasons (not safety or efficacy failures). It is now available as a compounded bulk under the FDA's interim 503A Category 1 policy, meaning FDA does not intend enforcement action against its compounding [10]. Because it works upstream of GH, it preserves the pituitary's own somatostatin-and-IGF-1 feedback loops and the natural pulsatile pattern of GH release.
What does sermorelin do to the body?
Sermorelin binds the GHRH receptor on pituitary somatotrophs and activates the cAMP/PKA pathway that stimulates synthesis and pulsatile release of growth hormone [10]. In prepubertal GH-deficient children, once-daily subcutaneous sermorelin accelerated linear growth, raising height velocity from approximately 4.1 cm/year to roughly 7–8 cm/year in the first year, without generating excessive IGF-1 [11]. For adults, the most relevant class-level RCT used a full-length GHRH analog (tesamorelin) rather than sermorelin itself, but demonstrated favorable effects on cognition, IGF-1 and body composition in older adults [8]. Sermorelin's own adult evidence base is thinner than its community popularity might suggest [9].
Does sermorelin work?
For its approved pediatric indication, the evidence is clear — multicenter trial data show accelerated linear growth in GH-deficient children [11]. For adult wellness applications (body composition, anti-aging), the evidence is much thinner. A 2008 Annals of Internal Medicine editorial by Blackman explicitly judged that using growth hormone secretagogues to prevent or treat the effects of aging is "not yet ready for prime time," citing the lack of rigorous long-term efficacy and safety data [9]. That editorial position has not been overturned. Whether sermorelin's physiologic properties translate to meaningful adult benefits remains an open research question, not an established fact.
How long does it take for sermorelin to work?
Sermorelin's short half-life (under the ten-minute range for the natural GHRH sequence) means each dose acts quickly at the pituitary and clears rapidly. In the pediatric GH-deficiency trial, linear growth improvement was measured over the course of the first year of daily treatment [11]; it is not a rapid-effect compound in any validated human study. This site does not provide dosing or timing recommendations. The class-level adult cognition study used 20 weeks of daily subcutaneous GHRH-analog stimulation before measuring outcomes [8] — suggesting the time horizon for any detectable adult effect, if one exists, is measured in weeks to months.
What is tesamorelin?
Tesamorelin is a synthetic analog of full-length GHRH(1-44)-NH2, modified at the N-terminus with a trans-3-hexenoic acid group that blocks the enzyme DPP-IV and extends plasma stability [1][13]. It is the only FDA-approved compound on this desk: NDA 022505 approved in November 2010 specifically to reduce excess abdominal fat in HIV-infected adults with antiretroviral-related lipodystrophy. Outside that indication it has no approved human use; all other applications are investigational [13].
What does tesamorelin do?
In its approved indication, tesamorelin reduces visceral adipose tissue. A 2026 meta-analysis of five randomized controlled trials found a mean visceral fat reduction of 27.71 cm², a trunk-fat reduction of 1.18 kg, a hepatic fat fraction reduction of 4.28%, and a lean mass increase of 1.42 kg, all statistically significant (P<0.001) and without serious adverse events [12]. In a 52-week extension trial, VAT reduction was sustained at −18% versus baseline [16]. The mechanism is stimulation of endogenous pulsatile GH secretion via GHRH-receptor binding, which drives preferential lipolysis in visceral fat [15].
How does tesamorelin work?
Tesamorelin binds the GHRH receptor on anterior-pituitary somatotroph cells, activating the Gs/adenylyl cyclase/cAMP/PKA cascade that triggers pulsatile GH secretion [1]. GH then drives hepatic IGF-1 production, and together GH and IGF-1 promote lipolysis — most prominently in visceral adipose tissue. In a mechanistic study in 13 healthy men, two weeks of tesamorelin raised mean overnight GH by 0.5 μg/L and IGF-1 by 181 μg/L, without significantly affecting fasting glucose or insulin-stimulated glucose uptake [15]. Because tesamorelin amplifies the body's own pulsatile rhythm rather than replacing GH, physiologic somatostatin and IGF-1 feedback remains operative.
Will tesamorelin help me lose belly fat?
For the specific population in the approved indication — HIV-infected adults on antiretroviral therapy with documented lipodystrophy — the RCT evidence for visceral fat reduction is robust [12][14]. For people outside that specific context, tesamorelin is not an approved treatment, and this site gives no medical advice on its use [13]. Importantly, visceral fat reaccumulates within weeks of stopping tesamorelin, meaning any benefit requires continued use [16]. Generalizability to non-HIV populations is mechanistically plausible but not established by large randomized controlled trials.